ABSTRACT
The Li-Fraumeni syndrome, resulting from TP53 germline mutations, represents one of the most devastating genetic predispositions to cancer. Recently, the MDM2 SNP309 (T>G variation) was shown to be associated with accelerated tumour formation in TP53 mutation carriers. The impact of the common TP53 codon 72 polymorphism on cancer risk remains controversial. We have therefore investigated the effect of these two polymorphisms in 61 French germline TP53 mutation carriers. The mean age of tumour onset in MDMD2 SNP309 G allele carriers (19.6 years) was significantly different from that observed in patients homozygous for the T allele (29.9 years, p<0.05). For the TP53 codon 72 polymorphism, the mean age of tumour onset in Arg allele carriers (21.8 years) was also different from that of Pro/Pro patients (34.4 years, p<0.05). We observed a cumulative effect of both polymorphisms since the mean ages of tumour onset in MDM2 G and TP53 Arg alleles carriers (16.9 years), and in patients with the MDM2 T/T and TP53 Pro/Pro genotype (43 years), were clearly different (p<0.02). Therefore, our results confirm the impact of the MDM2 SNP309 G allele on the age of tumour onset in germline TP53 mutation carriers, and suggest that this effect may be amplified by the TP53 72Arg allele.
Polymorphisms affecting p53 degradation represent therefore one of the rare examples of modifier genetic factors identified so far in Mendelian predispositions to cancer. towards MDM2 compared to the 72Pro variant, [5] we speculated that the p.Arg72Pro polymorphism might also influence the age of tumour onset in germline TP53 mutation carriers.
The impact of this polymorphism, as a risk factor in sporadic cancers, [6] or as a modifier factor in Mendelian forms of cancers such as BRCA1-related breast cancers, [7] has already been analysed, but the results are controversial.
We have therefore investigated the effect on tumorigenesis of these 2 polymorphisms in 61 affected or unaffected germline TP53 mutation carriers collected by the French LFS network.
METHODS

Patients
Sixty-one affected or unaffected germline TP53 mutation carriers, from 41 unrelated LFS families collected by the French LFS network, were investigated. Clinical characteristics of the families and description of the mutations are available upon request. DNA analysis was performed after informed consent was obtained.
HAL author manuscript inserm-00128004, version 1
MDM2 genotyping
The first intron of MDM2 was PCR-amplified using primers 5'-AGGTCTCCGCGGGAGTTC-3' and 5'-CTGCCCACTGAACCGGC-3'. PCR was performed in a 25 µL volume containing 100 ng of genomic DNA, 1.2 mM MgCl2, 160 µM dNTPs, 0.4 µM of each primer and 1 unit of Taq DNA polymerase (ABgene). After a denaturation step of 3 min at 95°C, the PCR consisted of 35 cycles of 10 s at 94°C, 10 s at 60°C, and 10 s at 72°C, and was followed by a final extension step of 7 min at 72°C. After purification of the PCR products using the QIAquick Gel Extraction Kit (Qiagen), sequencing analysis of the MDM2 SNP309 was performed using the PRISM Ampli Taq FS Ready Reaction Dye Terminators sequencing kit (PE Applied Biosystems) and a PE Applied Biosystems 377 automated DNA sequencer.
Determination of the phase of the TP53 codon 72 polymorphism
The phase (cis or trans) of the TP53 codon 72 polymorphism, relative to the germline mutation, was determined in the Arg/Pro heterozygotes, by cloning either PCR-amplified genomic DNA in bacteria, using primers encompassing exons 4 to 5, 7 or 8 or PCR-amplified cDNA in yeast, as previously described.
[8]
Statistical analysis
Analysis of variance was used to compare the mean age of onset between the different groups and a χ 2 was used to compare the distribution of tumour types between the different genotypes;
RESULTS and DISCUSSION
For MDM2, the observed frequencies in our series for the SNP309 T/T, T/G, and G/G genotypes were 37%, 46%, and 17%, respectively ( 1B) .
Since the potential effect of the codon 72 polymorphism may depend on its cis or trans position relative to the germline mutation, we determined the phase in the Arg/Pro heterozygotes, but we did not detect any significant effect of the phase on the age of tumour onset. (table 3) . The difference between these three groups was highly significant (p<0.001), suggesting a cumulative effect of both polymorphisms.
We did not detect any effect of these polymorphisms on the tumour type in our series.
Indeed, the comparison of the tumour type, stratified into three categories (breast, sarcoma, other cancer), between individuals with at risk genotypes at both loci and individuals with other genotypes was not significant ( 2=4.50). In each family, we obtaines DNA samples only from a limited number of affected individuals (1-3 people), which hampered the analysis of the impact of the polymorphisms on the tumour type within each family. Neither the MDM2 SNP309, nor the TP53 codon 72 polymorphism could explain the incomplete penetrance in males of germline TP53 mutations that we had previously estimated at 41% at age 45 (versus 84% in females). [9] HAL author manuscript inserm-00128004, version 1 Therefore, our results confirm the impact of the MDM2 SNP309 G allele on the age of tumour onset in germline TP53 mutation carriers, and suggest that this effect may be amplified by the TP53 72Arg allele, although this latter observation required to be confirmed on a larger series of germline TP53 mutation carriers. Polymorphisms affecting p53 degradation represent therefore one of the rare examples of modifier genetic factors identified so far in Mendelian predispositions to cancer. 
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